Merck & Company Inc (MRK)

U.S. FDA Accepts sBLA for ENFLONSIA™(clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season